Comprehensive registry of esophageal cancer in Japan, 2013

Abstract

Background: Esophageal cancer is the eighth most common cause of cancer mortality in Japan. More than 11,000 people had died from esophageal cancer in 2018. The Japan Esophageal Society has collected the data on patients' characteristics, performed treatment, and outcomes annually.

Methods: We analyzed the data of patients who had first visited the participating hospitals in 2013. In 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) and UICC TNM Classification 7th were used for cancer staging RESULTS: A total of 8019 cases were registered from 334 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.8% and 6.3%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 88.3%, 32.4%, 24.4%, and 59.3%, respectively. Esophagectomy was performed in 4910 cases. The operative and the hospital mortality rates were 0.77% and 1.98%, respectively. The survival curves showed a good discriminatory ability both in the clinical and pathologic stages by the JES system. The 5-year survival rate of patients with pStage IV in the UICC classification that included patients with supraclavicular node metastasis was better than that of patients with pStage IVb in JES classification.

Conclusion: We hope this report contributes to improving all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Keywords: Chemoradiotherapy; Chemotherapy; Endoscopic resection; Esophageal cancer; Esophagectomy.

Fig. 1

Survival of patients treated with EMR/ESD

Fig. 2

Survival of patients treated with EM/ESD according to the pathological depth of tumor invasion, pT(JES 10th)

Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Fig. 5

Survival of patients treated with definitive chemoradiotheraphy according to clinical stage (UICC TNM 7th)

Fig. 6

Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)

Fig. 7

Survival of patients who underwent esophagectomy

Fig. 8

Survival of patients who underwent eseophagectomy according to clinical stage (JES 10th)

Fig. 9

Survival of patients who underwent esophagectomy according to clinical stage (UICC TNM 7th)

Fig. 10

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Fig. 11

Survival of patients who underwent esophagectomy according to lymph node metastasis (JES 10th)

Fig. 12

Survival of patients who underwent esophagectomy according to lymph node metastasis (UICC TNM 7th)

Fig. 13

Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)

Fig. 14

Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)

Fig. 15

Survival of patients who underwent esophagectomy according to residual tumor (R)